High-dose dual therapy bismuth-containing quadruple therapy for eradication: a systematic review and meta-analysis with trial sequential analysis

High-dose dual therapy bismuth-containing quadruple therapy for eradication: a systematic review and meta-analysis with trial sequential analysis

Background and objective: Recently, a large number of trials on proton pump inhibitor-amoxicillin-containing high-dose dual therapy (HDDT) versus bismuth-containing quadruple therapy (BQT) for Helicobacter pylori ( H. pylori ) eradication have been published with controversial and inconsistent concl...

Full description

Bibliographic Details
Main Authors:	Ben-Gang Zhou, Yu-Zhou Mei, Min Zhang, Xin Jiang, Yao-Yao Li, Yan-Bing Ding
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-01-01
Series:	Therapeutic Advances in Gastroenterology
Online Access:	https://doi.org/10.1177/17562848221147756

Similar Items

Eradication efficacy of high-dose amoxicillin and proton pump inhibitor compared with quadruple therapy contained bismuth in the treatment of Helicobacter pylori
by: Eskandar Hajiani, et al.
Published: (2022-01-01)

Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and <i>Helicobacter pylori</i> Eradication Therapy
by: Yingchao Sun, et al.
Published: (2022-11-01)

Generalization and safety of the second-line levofl oxacin or Bismuth-based quadruple therapy for Helicobacter eradication
by: Bowen Hu, et al.
Published: (2023-11-01)

Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy bismuth-containing quadruple therapy for infection: a multicenter, randomized controlled clinical trial
by: Hao Mei, et al.
Published: (2022-12-01)

High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of helicobacter pylori infection: A meta-analysis of randomized controlled trials
by: Chong Zhang, et al.
Published: (2023-01-01)

Efficacy analysis of empirical bismuth quadruple therapy, high-dose dual therapy, and resistance gene-based triple therapy as a first-line Helicobacter pylori eradication regimen – An open-label, randomized trial
by: Jiang Xin, et al.
Published: (2023-07-01)

Effects of 14-days bismuth- and tetracycline-containing quadruple therapy with concomitant regimen for the first line Helicobacter pylori eradication
by: Arash Kazemi, et al.
Published: (2023-09-01)

Minocycline/Amoxicillin-Based Bismuth Quadruple Therapy for <i>Helicobacter pylori</i> Eradication: A Pilot Study
by: Senlin You, et al.
Published: (2024-02-01)

Comparison of eradication rates of moxifloxacin–rifabutin triple therapy and bismuth quadruple therapy as second‐line regimens in patients with peptic ulcers
by: Chang Min Lee, et al.
Published: (2022-09-01)

Sequential therapy versus quadruple therapy for Helicobacter pylori eradication: A prospective double‐blinded randomized controlled trial
by: Elham Tabesh, et al.
Published: (2024-01-01)

Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials
by: Ben-Gang Zhou, et al.
Published: (2023-01-01)

Comparison of Sequential, Hybrid, and Quadruple Therapy Protocols in Helicobacter pylori Eradication: A Single-Center Study
by: Ersin Kuloğlu, et al.
Published: (2022-10-01)

The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for eradicating Helicobacter pylori: a systematic review and meta-analysis of randomized controlled trials
by: Yin Chen, et al.
Published: (2024-04-01)

Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment of infection: a systematic review and meta-analysis
by: Gaoyan Yao, et al.
Published: (2023-10-01)

A Simplified Low-Dose 10-Day Quadruple Therapy with a Galenic Formulation of Bismuth Salicylate Is Highly Effective for <i>Helicobacter pylori</i> Eradication
by: Maria Pina Dore, et al.
Published: (2023-01-01)

Second-Line Bismuth-Containing Quadruple Therapy for <i>Helicobacter</i><i>pylori</i> Infection: A 12-Year Study of Annual Eradication Rates
by: Kiwon Shin, et al.
Published: (2021-07-01)

Empiric “Three-in-One” Bismuth Quadruple Therapy for Second-Line <em>Helicobacter pylori</em> Eradication: An Intervention Study in Southern Italy
by: Giuseppe Losurdo, et al.
Published: (2022-01-01)

The Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota after <i>Helicobacter pylori</i> Eradication: A Randomized Controlled Trial
by: Dingkun Wu, et al.
Published: (2022-11-01)

Bismuth, An Indispensable Component of Helicobacter pylori Eradication Therapy
by: Kyung Ho Song
Published: (2023-06-01)

Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed <i>Helicobacter pylori</i> Infection as 14 Days of Bismuth-Based Quadruple Therapy
by: Sang-Gon Moon, et al.
Published: (2022-07-01)

Can Sequential Therapy Replace Standard Triple Therapy as Eradication?
by: Sang Gyun Kim
Published: (2023-12-01)

Initial treatment with a single capsule containing half-dose quadruple therapy versus standard-dose dual therapy in hypertensive patients (QUADUAL): statistical analysis plan for a randomized, blinded, crossover trial
by: Xiexiong Zhao, et al.
Published: (2024-01-01)

Comparison of Eradication Rates Using Standard Triple Therapy and Sequential Therapy
by: Yuri Kim, et al.
Published: (2023-12-01)

Comparison of Sequential and Concomitant Therapy for Eradication of Helicobacter Pylori
by: Faisal Shabbir, et al.
Published: (2022-11-01)

Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial)
by: Nuttapat Tungtrongchitr, et al.
Published: (2024-04-01)

Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol
by: ShaoWei Han, et al.
Published: (2023-07-01)

10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: a randomised, open-label, non-inferiority trialResearch in context
by: Er-Hsiang Yang, et al.
Published: (2024-04-01)

Bismuth subcitrate in eradication regimens
by: P. L. Scherbakov, et al.
Published: (2016-12-01)

Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial
by: Chang Kyo Oh, et al.
Published: (2023-12-01)

Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of <i>Helicobacter pylori</i> Infection
by: Jeemyoung Kim, et al.
Published: (2022-01-01)

Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial
by: Chen Chen, et al.
Published: (2024-04-01)

Standard Bismuth Quadruple Therapy versus Concomitant Therapy for the First-Line Treatment of <i>Helicobacter pylori</i> Infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Rocco Maurizio Zagari, et al.
Published: (2023-05-01)

The efficacy and safety of vonoprazan–amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis
by: Jia-Hui Feng, et al.
Published: (2023-08-01)

Metagenomic Changes of Gut Microbiota following Treatment of <i>Helicobacter pylori</i> Infection with a Simplified Low-Dose Quadruple Therapy with Bismuth or <i>Lactobacillus reuteri</i>
by: Maria Pina Dore, et al.
Published: (2022-07-01)

USE OF BISMUTH DRUGS IN THERAPY OF GASTROENTEROLOGIC PATIENTS AND IN ERADICATION SCHEMES TAKING INTO ACCOUNT MAASTRICHT V RECOMMENDATIONS
by: O. N. Minushkin, et al.
Published: (2017-11-01)

14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: A prospective, randomized controlled trial
by: Qinyu Yang, et al.
Published: (2023-02-01)

Vonoprazan-based Dual and Triple Therapy for Helicobacter pylori Eradication
by: Jin Hee Noh, et al.
Published: (2023-09-01)

The Efficacy of Levofloxacin versus Clarithromycin in Primary Quadruple Therapy for the Eradication of Helicobacter Pylori: A Prospective Randomized Controlled Clinical Trial Study
by: Vahid Sebghatollahi, et al.
Published: (2020-06-01)

A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating <i>Helicobacter pylori</i>-Infected Duodenal Ulcers: A Multicenter, Opened, Randomized Controlled Trial in China
by: Jingshu Chi, et al.
Published: (2022-12-01)

Efficacy and safety of high-dose ilaprazole-amoxicillin dual therapy for Helicobacter pylori eradication: a prospective, single-center, randomized trial
by: Jianping Cheng, et al.
Published: (2023-11-01)